UK study finds equitable use of magnesium sulfate for preterm births

Researchers have examined NHS England maternity and neonatal records spanning a decade—from 2014 to 2024—to determine whether sociodemographic factors influence the use of antenatal magnesium sulfate. The analysis focused on women at risk of very preterm birth, a group for whom magnesium sulfate is routinely recommended to safeguard fetal brain development and lower the incidence of cerebral palsy.

The study’s objective was to identify any disparities in treatment uptake across different population groups, such as variations by age, ethnicity, socioeconomic status, or geographic region. By mapping prescription patterns against demographic data, the researchers aim to uncover whether certain communities receive the intervention at lower rates, which could signal gaps in care delivery or access.

While the findings of the analysis are not yet disclosed, the investigation underscores the importance of equitable clinical practice. Should significant differences emerge, the results could prompt targeted policy measures to ensure that all at‑risk mothers receive the recommended neuroprotective therapy, thereby improving neonatal outcomes nationwide.